298 related articles for article (PubMed ID: 27013699)
41. Theranostic application of
Li C; Liu J; Yang X; Yang Q; Huang W; Zhang M; Zhou D; Wang R; Gong J; Miao Q; Kang L; Yang J
Eur J Nucl Med Mol Imaging; 2022 Dec; 50(1):168-183. PubMed ID: 36063202
[TBL] [Abstract][Full Text] [Related]
42. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer.
Liu Z; Li ZB; Cao Q; Liu S; Wang F; Chen X
J Nucl Med; 2009 Jul; 50(7):1168-77. PubMed ID: 19525469
[TBL] [Abstract][Full Text] [Related]
43. Tumor and organ uptake of (64)Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies.
Lee JH; Kim H; Yao Z; Lee SJ; Szajek LP; Grasso L; Pastan I; Paik CH
Nucl Med Biol; 2015 Nov; 42(11):880-6. PubMed ID: 26307499
[TBL] [Abstract][Full Text] [Related]
44. Noninvasive Detection of HER2 Expression in Gastric Cancer by
Guo X; Zhu H; Zhou N; Chen Z; Liu T; Liu F; Xu X; Jin H; Shen L; Gao J; Yang Z
Mol Pharm; 2018 Nov; 15(11):5174-5182. PubMed ID: 30251865
[TBL] [Abstract][Full Text] [Related]
45. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
46. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts.
Paudyal B; Paudyal P; Oriuchi N; Hanaoka H; Tominaga H; Endo K
Cancer Sci; 2011 Jan; 102(1):117-21. PubMed ID: 21070475
[TBL] [Abstract][Full Text] [Related]
47. Comparison of two site-specifically (18)F-labeled affibodies for PET imaging of EGFR positive tumors.
Su X; Cheng K; Jeon J; Shen B; Venturin GT; Hu X; Rao J; Chin FT; Wu H; Cheng Z
Mol Pharm; 2014 Nov; 11(11):3947-56. PubMed ID: 24972326
[TBL] [Abstract][Full Text] [Related]
48. PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog.
Dijkgraaf I; Franssen GM; McBride WJ; D'Souza CA; Laverman P; Smith CJ; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2012 Jun; 53(6):947-52. PubMed ID: 22570329
[TBL] [Abstract][Full Text] [Related]
49. Targeting Phosphatidylserine with a
Perreault A; Richter S; Bergman C; Wuest M; Wuest F
Mol Pharm; 2016 Oct; 13(10):3564-3577. PubMed ID: 27608290
[TBL] [Abstract][Full Text] [Related]
50. Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer.
Jiang D; Im HJ; Sun H; Valdovinos HF; England CG; Ehlerding EB; Nickles RJ; Lee DS; Cho SY; Huang P; Cai W
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1296-1305. PubMed ID: 28265738
[TBL] [Abstract][Full Text] [Related]
51. Development of
Woo SK; Jang SJ; Seo MJ; Park JH; Kim BS; Kim EJ; Lee YJ; Lee TS; An GI; Song IH; Seo Y; Kim KI; Kang JH
J Nucl Med; 2019 Jan; 60(1):26-33. PubMed ID: 29777007
[TBL] [Abstract][Full Text] [Related]
52. In vivo small-animal PET/CT of EphB4 receptors using 64Cu-labeled peptide.
Xiong C; Huang M; Zhang R; Song S; Lu W; Flores L; Gelovani J; Li C
J Nucl Med; 2011 Feb; 52(2):241-8. PubMed ID: 21233177
[TBL] [Abstract][Full Text] [Related]
53. Anti‑tissue factor antibody‑mediated immuno‑SPECT imaging of tissue factor expression in mouse models of pancreatic cancer.
Sugyo A; Aung W; Tsuji AB; Sudo H; Takashima H; Yasunaga M; Matsumura Y; Saga T; Higashi T
Oncol Rep; 2019 Apr; 41(4):2371-2378. PubMed ID: 30816521
[TBL] [Abstract][Full Text] [Related]
54. Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer.
von Forstner C; Egberts JH; Ammerpohl O; Niedzielska D; Buchert R; Mikecz P; Schumacher U; Peldschus K; Adam G; Pilarsky C; Grutzmann R; Kalthoff H; Henze E; Brenner W
J Nucl Med; 2008 Aug; 49(8):1362-70. PubMed ID: 18632830
[TBL] [Abstract][Full Text] [Related]
55. Development and preclinical studies of
Lam K; Chan C; Reilly RM
MAbs; 2017 Jan; 9(1):154-164. PubMed ID: 27813707
[TBL] [Abstract][Full Text] [Related]
56. In Vivo Imaging of the Programmed Death Ligand 1 by
González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
[TBL] [Abstract][Full Text] [Related]
57. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
[TBL] [Abstract][Full Text] [Related]
58. A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor.
Li F; Jiang S; Zu Y; Lee DY; Li Z
J Nucl Med; 2014 Sep; 55(9):1525-31. PubMed ID: 24970912
[TBL] [Abstract][Full Text] [Related]
59. 64Cu-labeled 2-(diphenylphosphoryl)ethyldiphenylphosphonium cations as highly selective tumor imaging agents: effects of linkers and chelates on radiotracer biodistribution characteristics.
Yang CT; Kim YS; Wang J; Wang L; Shi J; Li ZB; Chen X; Fan M; Li JJ; Liu S
Bioconjug Chem; 2008 Oct; 19(10):2008-22. PubMed ID: 18763821
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
